Takeda Adds Exelixis Arrow To Oncology Quiver
Takeda's acquisition of Japanese rights to Exelixis' lead product fills a gap in the oncology portfolio while adding another piece to the US company's global licensing jigsaw.
Takeda's acquisition of Japanese rights to Exelixis' lead product fills a gap in the oncology portfolio while adding another piece to the US company's global licensing jigsaw.